Cerebral amyloid angiopathy (CAA) is a silent cause of lobar intracerebral hemorrhagic stroke commonly seen in older adults and is accompanied by dementia. Although, a small percentage of patients develop the disease due to mutations in APP, CST3 and ITM2B with different presentations including hemorrhagic stroke and dementia at a much younger age. All CAA cases are resulted from gradual and progressive amyloid deposition in the walls of cerebrovascular system.
Currently, there is no cure for CAA and its risk factors are yet to be fully determined, specifically for prevention interventions. Therefore, an update on new research findings is timely, adding to the value of the upcoming 8th International Cerebral Amyloid Angiopathy (CAA) Conference, Perth, Western Australia (3-5th November 2022). This Research Topic will include basic research, animal models and human studies with clinical trial or experimental design examining the effects of preventive methods on future risk, delaying the clinical diagnosis, or modifying the course of the disease progression. We will also consider review papers.
The primary aim of this Research Topic is to provide a publishing platform for cerebral amyloid angiopathy (CAA) research including basic and translational research into understanding its underlying mechanisms, risk factors, natural history as well as the pathogenesis pathways. Such research will inform screening methods as well as preventive and treatment interventions. Furthermore, most individuals diagnosed with Alzheimer’s disease (AD) have some degree of CAA. Therefore, understanding CAA will inform research into AD.
This project is interested in basic, animal, and human studies including observational/epidemiological, clinical trials, as well as natural history of both sporadic and non-sporadic CAA. Translational human studies are critical in understanding the effects of risk factors modification on prevention of CAA and its accompanied dementia and clinical manifestation of the disease. Therefore, this Research Topic will promote prevention studies, novel screening and diagnostic measures, as well as lifestyle modification trials to delay or halt CAA progression in both young and older individuals.
Research findings that can improve our understanding of the underlying mechanism(s), natural history, imaging and biofluid markers as well as clinical manifestations, modifiable lifestyle risk factors and pathogenesis of CAA will fall within the scope of this Research Topic.
The following list includes examples of general themes for CAA research that will be considered. However, we encourage submission of any CAA related manuscript that goes beyond the scope of the following examples:
1. Amyloid-related imaging abnormalities (ARIA) and Cerebral amyloid angiopathy-related inflammation
2. Iatrogenic CAA
3. Novel CAA Biomarkers (imaging, CSF and other biofluids)
4. Perivascular clearance, vasomotion, and CAA
5. Innovative therapeutic approaches CAA
6. Neuropsychiatric and neuropsychological findings of CAA
7. CAA and Alzheimer’s disease: Neuropathological correlates and dementia syndrome
8. Lifestyle risk factors including physical exercise, sleep, diet, and environmental toxins
Note: The list is not exclusionary of other potential CAA research contributions and specifically the importance of null result manuscripts, given sound scientific methodology has been adhered to. Meta-analysis, and systematic and narrative reviews are also encouraged.
Cerebral amyloid angiopathy (CAA) is a silent cause of lobar intracerebral hemorrhagic stroke commonly seen in older adults and is accompanied by dementia. Although, a small percentage of patients develop the disease due to mutations in APP, CST3 and ITM2B with different presentations including hemorrhagic stroke and dementia at a much younger age. All CAA cases are resulted from gradual and progressive amyloid deposition in the walls of cerebrovascular system.
Currently, there is no cure for CAA and its risk factors are yet to be fully determined, specifically for prevention interventions. Therefore, an update on new research findings is timely, adding to the value of the upcoming 8th International Cerebral Amyloid Angiopathy (CAA) Conference, Perth, Western Australia (3-5th November 2022). This Research Topic will include basic research, animal models and human studies with clinical trial or experimental design examining the effects of preventive methods on future risk, delaying the clinical diagnosis, or modifying the course of the disease progression. We will also consider review papers.
The primary aim of this Research Topic is to provide a publishing platform for cerebral amyloid angiopathy (CAA) research including basic and translational research into understanding its underlying mechanisms, risk factors, natural history as well as the pathogenesis pathways. Such research will inform screening methods as well as preventive and treatment interventions. Furthermore, most individuals diagnosed with Alzheimer’s disease (AD) have some degree of CAA. Therefore, understanding CAA will inform research into AD.
This project is interested in basic, animal, and human studies including observational/epidemiological, clinical trials, as well as natural history of both sporadic and non-sporadic CAA. Translational human studies are critical in understanding the effects of risk factors modification on prevention of CAA and its accompanied dementia and clinical manifestation of the disease. Therefore, this Research Topic will promote prevention studies, novel screening and diagnostic measures, as well as lifestyle modification trials to delay or halt CAA progression in both young and older individuals.
Research findings that can improve our understanding of the underlying mechanism(s), natural history, imaging and biofluid markers as well as clinical manifestations, modifiable lifestyle risk factors and pathogenesis of CAA will fall within the scope of this Research Topic.
The following list includes examples of general themes for CAA research that will be considered. However, we encourage submission of any CAA related manuscript that goes beyond the scope of the following examples:
1. Amyloid-related imaging abnormalities (ARIA) and Cerebral amyloid angiopathy-related inflammation
2. Iatrogenic CAA
3. Novel CAA Biomarkers (imaging, CSF and other biofluids)
4. Perivascular clearance, vasomotion, and CAA
5. Innovative therapeutic approaches CAA
6. Neuropsychiatric and neuropsychological findings of CAA
7. CAA and Alzheimer’s disease: Neuropathological correlates and dementia syndrome
8. Lifestyle risk factors including physical exercise, sleep, diet, and environmental toxins
Note: The list is not exclusionary of other potential CAA research contributions and specifically the importance of null result manuscripts, given sound scientific methodology has been adhered to. Meta-analysis, and systematic and narrative reviews are also encouraged.
